SURF News and Press, Surface Oncology Inc. From 04/23/20

CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1 clinical trial of i...

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...

CAMBRIDGE, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1/1b clinical trial of its...

Surface Oncology (NASDAQ: SURF ): Q4 GAAP EPS of -$0.57 in-line. Revenue of $0.44M (-95.5% Y/Y) misses by $1.11M . Press Release More news on: Surface Oncology, Inc., Earnings news and commentary, Healthcare stocks news, ,

CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth...

CAMBRIDGE, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert...

Pfizer Misses Q4 Target, offers Soft Guidance Pfizer ( PFE ) stock stumbled as the company reported lower than expected numbers for its fourth quarter. It also provided lackluster guidance for the upcoming FY 2020. The company’s revenue fell as it lost exclusivity on its key drugs...

The FDA has signed off on IND applications from Surface Oncology (NASDAQ: SURF ) for Phase 1 studies of candidates SRF617 and SRF388. More news on: Surface Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Surface Oncology (NASDAQ: SURF ) is up 13.8% postmarket after the FDA cleared Investigational New Drug applications for antibody candidates SRF617 and SRF388. More news on: Surface Oncology, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Gainers: XLRN   +79.4% . SURF   +17.2% . DESP   +8.7% . KBWB   +5.8% . BCRX   +4.4% . More news on: Acceleron Pharma Inc., Surface Oncology, Inc., Despegar.com, Corp., Stocks on the move, , , News on ETFs Read more ...